AAPS PharmSciTech

, Volume 4, Issue 1, pp 71–79 | Cite as

Study of isopropyl myristate microemulsion systems containing cyclodextrins to improve the solubility of 2 model hydrophobic drugs

  • Indranil Nandi
  • Mohammad Bari
  • Hemant Joshi


The objectives of this project were to evaluate the effect of alkanols and cyclodextrins on the phase behavior of an isopropyl myristate microemulsion system and to examine the solubility of model drugs. Triangular phase diagrams were developed for the microemulsion systems using the water titration method, and the solubility values of progesterone and indomethacin were determined using a conventional shake-flask method. The water assimilation capacities were determined to evaluate the effective microemulsion formation in different systems. The alkanols showed higher microemulsion formation rates at higher concentrations. A correlation between the carbon numbers of the alkanol and water assimilation capacity in the microemulsions studied was observed; isobutanol and isopentanol produced the best results. The addition of cyclodextrins showed no effect or had a negative effect on the microemulsion formation based on the type of cyclodextrin used. Isopropyl myristate-based microemulsion systems alone could increase the solubility values of progesterone and indomethacin up to 3300-fold and 500-fold, respectively, compared to those in water. However, the addition of cyclodextrins to the microemulsion systems did not show a synergistic effect in increasing the solubility values of the model drugs. In conclusion, microemulsion systems improve the solubility of progesterone and indomethacin. But the two types of cyclodextrins studied affected isopropyl myristatebased microemulsion systems negatively and did not improve the solubilization of 2 model drugs.


phase diagram microemulsion solubilization cyclodextrin surfactant progesterone indomethacin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ritschel WA, Adolph S, Ritschel GB, Schroeder T. Improvement of peroral absorption of cyclosporin A by microemulsions. Methods Find Exp Clin Pharmacol. 1990;12:127–134.PubMedGoogle Scholar
  2. 2.
    Kim CK, Ryuu SA, Park KM, Lim SL, Hwang SJ. Preparation and physiochemical characterization of phase inverted water/oil microemulsion containing cyclosporin. A Int J Pharm. 1996;147:131–134.CrossRefGoogle Scholar
  3. 3.
    Linn E.E. Microemulsion for intradermal delivery of cetyl alcohol and octyl dimethyl PABA. Drug Dev Ind Pharm. 1990;16:899–920.CrossRefGoogle Scholar
  4. 4.
    Garcia-Celma MJ, Azemar N, Pes MA, Solans C. Solubilization of antifungal drugs in water/POE (20) sorbitan monooleate/oil systems. Int J Pharm. 1994;105:77–81.CrossRefGoogle Scholar
  5. 5.
    Thevenin MA, Grossiord JL, Poelman MC. Sucrose esters/cosurfactant microemulsion systems for transdermal delivery: assessment of bicontinuous structures. Int J Pharm. 1996;137:177–186.CrossRefGoogle Scholar
  6. 6.
    Corswant CV, Thoren P, Engstrom S. Triglyceride-based microemulsion for intravenous administration of sparingly soluble substances. J Pharm Sci. 1998;87:200–208.CrossRefGoogle Scholar
  7. 7.
    D’ Cruz OJ, Yiv SH, Uckun FM. GM-144, a novel lipophilic vaginal contraceptive gel-microemulsion. AAPS Pharm Sci Tech. 2001;2(2):article 5.Google Scholar
  8. 8.
    Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins, II: in vivo drug delivery. J Pharm Sci. 1996;85:1142–1169.PubMedCrossRefGoogle Scholar
  9. 9.
    Piel G, Evrad B, Fillet M, Labres G, Dellatre L. Development of a non-surfactant parenteral formulation of miconazole by use of cyclodextrins. Int J Pharm. 1998;169:15–22.CrossRefGoogle Scholar
  10. 10.
    Loftsson T, Brewster ME. Pharmaceutical application of cyclodextrins, I: drug solubilization and stabilization. J Pharm Sci. 1996;85:1017–1025.PubMedCrossRefGoogle Scholar
  11. 11.
    Stella VJ, Rajewski RA. Cyclodextrins: their future in drug formulation and delivery. Pharm Res. 1997;14:556–567.PubMedCrossRefGoogle Scholar
  12. 12.
    Szente L, Szejtli J. Highly soluble cyclodextrin derivatives: chemistry, properties and trends in development. Adv Drug Deliv Rev. 1999;36:17–28.PubMedCrossRefGoogle Scholar
  13. 13.
    Dalmora ME, Oliveria AG. Inclusion complex of piroxicam with β-cyclodextrin and incorporation in hexadecyltrimethylammonium bromide based microemulsion. Int J Pharm. 1999;184:157–164.PubMedCrossRefGoogle Scholar
  14. 14.
    Dalmora ME, Dalmora SL, Oliveria AG. Inclusion complex with piroxicam with β-cyclodextrin and incorporation in cationic microemulsion: in vitro drug release and in vivo topical anti-inflammatory effect. Int J Pharm. 2001;222:45–55.PubMedCrossRefGoogle Scholar
  15. 15.
    Attwood D, Mallon C, Kristis G, Taylor CJ. A study of factors influencing the droplet size in nonionic oil-in-water microemulsions. Int J Pharm. 1992;88:417–422.CrossRefGoogle Scholar
  16. 16.
    Alany RG, Rades T, Agatonovic-Kustrin S, Davies NM, Tucker IG. Effects of alcohols and diols on phase behavior of quaternary systems. Int J Pharm. 2000;191:141–145.CrossRefGoogle Scholar
  17. 17.
    Pitha J, Milecki J, Fales H, Pannell L, Uekema K. Hydroxypropyl-β-cyclodextrin: preparation and characterization; effects on solubility of drugs. Int J Pharm. 1986;29:73–82.CrossRefGoogle Scholar
  18. 18.
    Nandi I, Bateson M, Bari M, Joshi H. Synergistic effect of PEG-400 and cyclodextrin to enhance solubility of progesterone. AAPS PharmSciTech. 2003;4(1) article 1.Google Scholar
  19. 19.
    Johnson KA, Shah DO. Effect of oil chain length and electrolytes on water solubilization in alcohol-free pharmaceutical microemulsions. J Colloid Interface Sci. 1985;107(1):269–271.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2003

Authors and Affiliations

  1. 1.Geneva Pharmaceutical Technology CorpDayton
  2. 2.Forest Laboratories IncInwood
  3. 3.Barr LaboratoriesPomona

Personalised recommendations